Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group
- 20 November 2017
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (33), 3753-3759
- https://doi.org/10.1200/jco.2017.74.4102
Abstract
Purpose Patients with organ dysfunction, prior or concurrent malignancies, and comorbidities are often excluded from clinical trials. Excluding patients on the basis of these factors results in clinical trial participants who are healthier and younger than the overall population of patients with cancer. Methods ASCO and Friends of Cancer Research established a multidisciplinary working group that included experts in trial design and conduct to examine how eligibility criteria could be more inclusive. The group analyzed current eligibility criteria; conducted original data analysis; considered safety concerns, potential benefits, research, and potential hurdles of this approach through discussion; and reached consensus on recommendations regarding updated eligibility criteria that prioritize inclusiveness without compromising patient safety. Results If renal toxicity and clearance are not of direct treatment-related concern, then patients with lower creatinine clearance values of > 30 mL/min should be included in trials. Inclusion of patients with mild to moderate hepatic dysfunction may be possible when the totality of the available nonclinical and clinical data indicates that inclusion is safe. Ejection fraction values should be used with investigator assessment of a patient’s risk for heart failure to determine eligibility. Patients with laboratory parameters out of normal range as a result of hematologic disease should be included in trials. Measures of patient functional status should be included in trials to better assess fit versus frail patients. Conclusion Expanding inclusion of these patients will increase the number and diversity of patients in clinical trials and result in a more appropriate population of patients.Keywords
This publication has 29 references indexed in Scilit:
- Anticipating the “Silver Tsunami”: Prevalence Trajectories and Co-Morbidity Burden among Older Cancer Survivors in the United StatesCancer Epidemiology, Biomarkers & Prevention, 2016
- Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907Journal of Clinical Oncology, 2016
- Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical TrialsJNCI Journal of the National Cancer Institute, 2015
- Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology StatementJournal of Clinical Oncology, 2015
- Modernizing Eligibility Criteria for Molecularly Driven TrialsJournal of Clinical Oncology, 2015
- Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroupJournal of Clinical Oncology, 2009
- Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug managementCancer, 2007
- Kidney function estimating equations: where do we stand?Current Opinion in Nephrology and Hypertension, 2006
- Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical TrialsJournal of Clinical Oncology, 2005
- The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal StudyJournal of Gerontology, 1976